Introduction
Multi-center trials have revealed that lowering blood pressure leads to reduction of cardiovascular mortality and morbidity (1) . However, the ability to identify hypertensive patients destined to suffer a fatal complication in the long presymptomatic phase of this condition is limited by the weak relationship between blood pressure level and the occurrence of complications. Arterial functional changes, such as arterial compliance and stiffness, are systemic complications caused by hypertension, and several methods to evaluate these changes have been reported. Recent epidemiologic and clinical studies have shown that aortic pulse wave velocity (PWV), a measure of arterial stiffness, is accelerated (2) and is a predictor of cardiovascular mortality in patients with end-stage renal disease (3), hypertension (4) , and diabetes mellitus (5) , and in older individuals (6) , independently of confounding factors such as age, blood pressure, and cardiac mass. These results support the hypothesis that monitoring of arterial stiffness under different medications could help both in risk assessment and risk reduction strategies. Thus, arterial stiffness measurements could serve as an important tool in clinical practice in hypertensive patients.
Second-derived photoplethysmography (SD-PTG) is also an established procedure to evaluate arterial functional change (7) . Takazawa et al. suggested that the b/a index, which was one of the parameters produced by SD-PTG might, reflect large arterial stiffness and that the d/a index indicates peripheral reflection (7) . Therefore, we analyzed the b/a and d/a ratios as representative parameters for SD-PTG. The vasoreactivity is also one of the arterial functional changes. Evaluating endothelial function is very complicated; however, forearm reactive hyperemia after upper arm ischemia partially represents endothelial function, and vasoreactivity evaluated by reactive hyperemia has been reported to be implicated in the pathogenesis of hypertensive complications (8) .
As described above, several methods for evaluating arterial functional change exist, and each evaluation is clinically important; however, the clinical usefulness of each method in hypertensive patients is still unclear. Therefore, we designed a hospital-based cohort study to evaluate the clinical importance of PWV, SD-PTG, and reactive hyperemia as predictors of cardiovascular events in hypertensive patients participating in the Non-invasive Atherosclerotic Evaluations in Hypertension (NOAH) study. Figure 1 shows a flow chart of the selection process of the study cohort. In our hospital, a total of 813 serial outpatients who had been diagnosed with essential hypertension were recruited between January 1998 and June 2004. Based on routine physical and laboratory examinations, we excluded from this study hypertensive patients with malignant diseases (n= 6) and arterial fibrillation (n= 29). Blinded specialists performed PWV, SD-PTG, and reactive hyperemia for every patient at the same time after 20 min of rest (n= 778); however, there was not sufficient PWV data for 13 patients; SD-PTG data were insufficient for 15 patients; and data for reactive hyperemia were lacking for 32 patients, leaving 718 hypertensive patients who were enrolled in this study. After performing a clinical survey for each patient as described below, we could not obtain sufficient information about cardiovascular events and/or mortality in 42 patients, and thus a final of 676 patients were investigated.
Methods

Study Population and Study Design
The characteristics for the 676 hypertensive patients are shown in Table 1 . As shown in Fig. 1 , two separate studies were performed in this work. In Study 1, we examined the prognostic impact of atherosclerotic evaluations in all participants, and in Study 2, we examined in patients who did not have history of stroke or cardiovascular disease (CVD). The 118 participants included in Study 1 had a history of cardiovascular events and atherosclerotic diseases defined as World Health Organization (WHO) grade 3 in 1999. To clarify the efficacy of each procedure (i.e., PWV, SD-PTG, and reactive hyperemia) in predicting cardiovascular events, we excluded patients who had a history of cardiovascular events, leaving 558 patients for the investigation in Study 2. The study protocol was approved by the hospital ethics committee, and written informed consent was obtained from all participants. A total of 293 patients were not treated with any antihypertensive drugs, and 383 patients were treated with one or more antihypertensive drugs: 244 patients with a calcium antagonist, 150 patients with an angiotensin II receptor blocker (ARB), 125 patients with an angiotensin converting enzyme (ACE) inhibitor, 76 patients with a β-blocker, 46 patients with a diuretic, and 27 patients with an α-blocker. An additional 180 patients were also treated with a statin.
Follow-Up Evaluation
Clinical follow-up was conducted by clinical visits, mailed questionnaires, and telephone contact every September from 2003. The questionnaire included the events of hypertensive complications described below and cause of death. We also confirmed responses in detail by comparing them against patient medical sheets. The primary endpoint of this study was new onset of stroke or CVD, such as a new onset of angina pectoris, myocardial infarction, or heart failure, or a rupture of an aortic aneurysm. Specialists diagnosed stroke by neurological disturbance for at least 24 h and evidence of infarction or bleeding using computed tomography or magnetic resource imaging, angina by typical chest pain without creatinine kinase release and positive ST change of stress electrocardiogram, and myocardial infarction by typical chest pain with a more than two-fold normal amount of creatinine kinase release and positive ST change of electrocardiogram. Heart failure was diagnosed by American Heart Association criteria and diagnosis of rupture of an aortic aneurysm was defined by computed tomography and clinical findings. The follow-up duration was considered to encompass the interval from the initial evaluation to the time of event onset or September 2006. The average follow-up period was 57.0±23.7 months.
Second-Derived Photoplethysmography
Measurements were performed in the morning with each patient in the supine position. Blood pressure was measured in the right upper arm after a 5-min rest using an automatic blood pressure meter (HEM-609; OMRON Healthcare Co., Kyoto, Japan). Three measurements taken 2 min apart were averaged. Blood pressure determination, SD-PTG, carotidfemoral PWV (cfPWV), and forearm blood flow measurements were performed in a controlled environment at 22±2°C, respectively. SD-PTG was performed by a Fukuda FCP-4731 with a model IB-70, as described previously (7, 9) . Briefly, the IB-70 device was a photoplethysmogram, equipped with double differentiation circuits, and the sensor was positioned on the cuticle of the index finger of the left hand. Photoplethysmography measures the changing absorption of light by hemoglobin, which is related to blood flow volume. The IB-70 performs automatic analysis of each second derivative of the photoplethysmographic waveform, which we called SD-PTG. The SD-PTG waveform consists of four waves in systole (a, b, c, and d) and one in diastole (e).
We measured the height of each wave from the baseline, with the values above baseline being considered positive and those under it negative. The b/a ratio was defined as the ratio of the height of the b-wave to that of the a-wave, and the d/a ratio as the height of the d-wave to that of the a-wave.
Determination of Pulse Wave Velocity
We evaluated PWV with the patient in a supine position after 20 min of rest. We determined PWV using a "FCP-4731" device (Fukuda Denshi Co., Tokyo, Japan), which allowed online pulse wave recording and automatic calculation. The pulse waveforms of the right carotid and femoral arteries were recorded non-invasively using a TY-306-Fukuda pressure-sensitive transducer (Fukuda Denshi Co.), and heart sounds were recorded at the same time. A preprocessor automatically analyzed the gain in each waveform and adjusted it for equality of the two signals. This procedure has been published in detail elsewhere (10) .
Determination of Reactive Hyperemia by Strain Gauge Plethysmography
We measured forearm blood flow by strain-gauge plethysmography (EC5R; D.E. Hokanson Inc., Bellevue, USA) as described by Komai et al. (10) . Briefly, with the subject in a supine position after a 5-min rest, a strain-gauge was applied to the area with the maximal forearm diameter. A venous occlusion cuff was wrapped around the upper arm, and 1% calibration waves were recorded. Then, the venous occlusion cuff was compressed at 40 mmHg. Immediately after compression, the blood flow began to elevate and reached a plateau 1-2 min after compression. This was regarded as the basic blood flow (vol%/min). The cuff pressure was then increased to 200 mmHg for a 5-min compression, and rapidly deflated to 40 mmHg. Antebrachial arterial blood flow (vol%/ min) at reactive hyperemia was calculated. 
Statistical Analysis
We classified subjects into four groups by quartile in ascending order for each evaluation. The values summarized in Tables 1-3 are presented as the mean±SD. Statistical analysis was performed using ANOVA by post-hoc test adjusted with Bonferroni/Dunn correction. An event-free curve was estimated via the Kaplan-Meier method. Patients were stratified according to quartiles of SD-PTG, PWV, or reactive hyperemia for the analysis of event-free rates. The log-rank test was used to compare the differences of event-free rates among these patient groups. To clarify the statistical significance between each quartile, we used a log-rank test for each two quartiles and non-adjusted Cox proportional hazard model to evaluate the relative risk and 95% confidence interval (CI). Baseline clinical variables for these patients were analyzed with the Cox proportional hazard model after adjusting for other common risk factors, such as gender, age, current smoking, presence of diabetes and hyperlipidemia, systolic and diastolic blood pressure and serum creatinine, and the hazard ratio with 95% confidence interval was given for each factor. Analyses were performed with commercially available software (Dr. SPSS II; SPSS Inc., Chicago, USA). Findings of p< 0.05 were considered significant.
Results
Patient Characteristics
Baseline clinical characteristics for each study are summarized in Table 1 Table 2 . The baseline characteristics for each evaluation in Study 1 are summarized in Table 3 . Each evaluation was associated with common risk factors; most notably, every evaluation was influenced by age and systolic blood pressure.
Results of Study 1
By the time of the follow-up survey, 52 of the 676 patients had suffered from stroke, 40 of the 676 patients had suffered from CVD, and 22 of the 676 patients had died. Figure 2A shows the results of the Kaplan-Meier analysis for occurrence of stroke and CVD. The event-free survival of PWV was significantly distributed by log-rank test (p< 0.0001), and that in 48 (28) 40 (25) 40 (23) 21 (12) 0.0033
29 (17) 37 (22) 33 (20) 48 (28) n.s.
HL (n (%))
99 (58) 80 (50) 96 (55) 101 (59) n.s.
(54)
99 (59) 83 (50) 100 (58) n.s. 34 (20) 41 (24) 37 (22) 27 (16) n.s.
SBP (mmHg)
28 (17) 42 (24) 36 (22) 42 (25) n.s.
HL (n (%))
90 (53) 94 (59) 105 (62) 89 (53) n.s.
(53)
101 (58) 98 (60) 85 (50) n.s. Figure 2B shows the results of the Kaplan-Meier analysis for total mortality. The event-free survival of PWV was significantly distributed by log-rank test (p= 0.0016), and that in patients with the highest quartile of PWV was significantly lower than that in patients in the 1st quartile (p= 0.0042; relative risk= 6.675; 95% CI: 1.506-29.584) and 2nd quartile (p= 0.0038; relative risk= 2.564; 95% CI: 2.234-8.973); however, there was no difference in reactive hyperemia or b/ a and d/a.
SBP (mmHg)
We also performed Cox proportional hazards model analysis for stroke and CVD after adjusting for common risk factors, such as gender, age, current smoking, presence of diabetes and hyperlipidemia, systolic and diastolic blood pressure and serum creatinine (Table 4 ). In the non-invasive evaluations of arterial functional changes, the fourth quartile value of PWV (relative risk= 2.717; 95% CI: 1.174-6.289; p= 0.0196) emerged as an independent risk factor along with age (per 10 years) (relative risk= 1.361; 95% CI: 1.056-1.755; p= 0.0174), current smoking (relative risk= 1.776; 95% CI: 1.067-2.954; p= 0.0270) and serum creatinine (relative risk= 1.730; 95% CI: 1.353-2.212; p< 0.0001). Moreover, the fourth quartile value of reactive hyperemia (relative risk= 0.416; 95% CI: 0.184-0.942; p= 0.0354) emerged as an independent risk factor along with age (per 10 years) (relative 
Results of Study 2
To clarify the influence of each arterial evaluation on adverse events in hypertensive patients, we excluded patients with a history of stroke and/or CVD (Fig. 1) . By the time of the follow-up survey, 36 of the 558 patients had suffered from stroke, 21 of the 558 patients had suffered from CVD, and 8 of the 558 patients had died. Figure 3 shows the results of the Kaplan-Meier analysis for occurrence of stroke and CVD. The event-free survival of PWV was significantly distributed by log-rank test (p= 0.0061), and that in patients with the highest quartile of PWV was significantly lower than that in patients in the 1st quartile (p= 0.0001; relative risk= 4.665; 95% CI: 1.991-10.928), 2nd quartile (p= 0.0074; relative risk= 2.526; 95% CI: 1.250-5.105) and 3rd quartile (p= 0.0061; relative risk= 2.563; 95% CI: 1.267-5.181). The event-free survival of reactive hyperemia was significantly distributed (p= 0.0445) and that in patients with the highest quartile of reactive hyperemia was significantly higher than that in patients in the 1st quartile (p= 0.0221; relative risk= 0.321; 95% CI: 0.117-0.885) and 3rd quartile (p= 0.0233; relative risk= 0.324; 95% CI: 0.119-0.879). There was no difference in the distribution in b/a and d/a; however, the event-free survival in patients in only the highest quartile of d/a was significantly lower than that in patients in the 1st quartile (p= 0.0317; relative risk= 2.412; 95% CI: 1.056-5.510). By the Kaplan-Meier analysis for total mortality, we could not find any significant distribution (data not shown). We also performed Cox proportional hazards model analysis for stroke and CVD after adjusting for common risk factors, such as gender, age, current smoking, presence of diabetes and hyperlipidemia, systolic and diastolic blood pressure and serum creatinine (Table 5 ). In the non-invasive evaluations of arterial functional changes, only the highest quartile value of PWV (relative risk= 4.152; 95% CI: 1.341-7.075; p= 0.0080) emerged as independent risk factors along with age (per 10 years) (relative risk= 1.407; 95% CI: 1.027-1.927; p= 0.0337) and presence of hyperlipidemia (relative risk= 1.975; 95% CI: 1.054-3.702; p= 0.0337).
Discussion
In the present study, we demonstrated that increased arterial stiffness as assessed by PWV contributes to increased incidence of stroke and CVD, and increased reactive hyperemia as evaluated by strain-gauge plethysmography contributes to decreased incidence of stroke and CVD in patients with essential hypertension independent of blood pressure and age.
The concept of using aortic stiffness to predict outcomes of hypertensive patients is still evolving. Previous cohort studies for hypertensive patients have been performed in France (4, 12) . These reports suggested that increased arterial stiffness as measured by PWV showed a prognostic impact on CVD in treated hypertensive patients. In the Japanese population, PWV was reported to be an independent risk factor for CVD in patients with end-stage renal dysfunction (13) . In the present study, we followed these results in Japanese hypertensive patients; moreover, we directly compared the prognostic impact of arterial functional changes evaluated by PWV, SD-PTG, and reactive hyperemia in a cohort study. As there have been no clinical trials to directly assess the usefulness of atherosclerotic evaluations, there is still disagreement regarding the optimal methods for assessing arterial functional changes. Our data suggested that increased arterial stiffness measured by PWV showed strong predictive effects on total mortality and morbidity of stroke and CVD in Japanese hypertensive patients. In addition, it was a risk factor for occurrence of stroke and CVD with higher reactive hyperemia and age, as analyzed by the Cox hazard model. Several reports evaluating the general population have indicated that decreased endothelially mediated vasodilatation of arteries has a prognostic impact on cardiovascular morbidity and mortality (14) . Furthermore, a previous cross-sectional study indicated that increased aortic stiffness was associated with endothelial dysfunction. In the present study, reactive hyperemia values in the highest quartile of hypertensive patients improved the prognosis of stroke and CVD. We considered reactive hyperemia measured by strain-gauge plethysmography could not strictly evaluate "endothelial function," because this device evaluates vasodilator response to post-ischemic reactive hyperemia. Although the methodology differs from that in previous studies (14, 15) , the results from prior work support our data, indicating that reactive hyperemia also might be an independent prognostic factor for the occurrence of stroke and CVD. Recently, a number of different methods and devices for evaluating the biomechanical properties of the aorta and other large arteries have become available. These methods may provide a more accurate and integrated picture of arterial stiffness. Therefore, to confirm the present results, further studies using a combination of techniques such as large and small artery compliance, stroke volume/pulse pressure, systemic arterial compliance, stiffness index, and augmentation index are needed (16) . Although several parameters measured by SD-PTG were related with aortic stiffness and peripheral reflections (7) and improved by antihypertensive therapy (9), the present study was the first to evaluate the predictive effects of the parameters b/a and d/a. We found that only the highest quartile of d/a was a significantly higher risk compared with the lowest quartile; however, we could not find any differences in b/a. Takazawa et al. (7) suggested that SD-PTG was reflected by peripheral arterial reaction, and b/a and d/a were significantly correlated with aging in a population study. We suspected that SD-PTG was not useful for predicting the effect on CVD in hypertensive patients, but that it might prove useful in a general population following a large cohort study in the future.
The present study suggested that PWV was more effective for predicting the risk of stroke and CVD in hypertensive patients than were SD-PTG and reactive hyperemia. Although we were unable to find a previous report establishing an upper or lower limit for PWV in a Japanese hypertensive population, a previous cohort study with a hypertensive population reported that the relative risk of developing CVD predicted by 1 SD of PWV (3.5 m/s) was 1.42 (p< 0.01) (17) , and that PWV in subjects who developed CVD events was 12.8±3.3 m/s, which was 1.3 m/s higher than that in subjects without CVD events. A French cohort study also revealed that the presence of a PWV of > 13 m/s, taken alone, appeared to be a strong predictor of cardiovascular mortality with high performance values (18) . According to our results, the mean value in the highest quartile of PWV was 11.24±1.05 m/s (range= 10.05-16.00 m/s). Therefore, we suspected that a PWV of around 10.0 to 11.0 m/s constituted the lower limit for increased risk of strok and CVD.
Study Limitations
The present study had several limitations. First, this cohort study was hospital-based but not a multi-center study. To avoid study bias and confirm the present results, a larger cohort and multi-center trials are needed. Second, patients who enrolled in this study received many kinds of antihypertensive treatment, and some patients received statin therapy. Recent reports indicate that treatment with ACE inhibitors (10, 19) , ARBs (20) or statins (21) improves arterial stiffness. As a result, taking these medications could contribute to better effects on survival. Because these medications would affect the prognosis in hypertensive patients, further studies according to the type of medications are needed. For this reason, the ability to generalize the present results to patients with untreated hypertension may be limited. Third, patients with PWV values in the highest quartile were older and had higher systolic blood pressure in the present study. The previous study reported that age and the presence of high blood pressure were the determinants of accelerated progression of aortic stiffness in treated hypertensive subjects (12) . These determinants would accelerate the progression of aortic stiffness during the follow-up period, resulting in a worse outcome. This limitation, however, does not concern the present conclusions, because PWV and age were accepted as independent risk factors, as shown by the Cox hazard model.
Conclusions
In patients with essential hypertension, higher arterial stiffness estimated by PWV was a better predictor of adverse outcome, whereas higher reactive hyperemia showed a weak correlation with a better outcome. These data support the desirability of increased use of PWV in the management of hypertensive patients in clinical practice; however, brachialankle PWV is widely used in Japan and is also an effective procedure. A a multi-center trial called the Japanese Trial on the Prognostic Implication of Pulse Wave Velocity (22) will begin soon, and may provide further data to support clinical PWV use in hypertensives. Furthermore, our results indicate that a reduction in arterial stiffness may be a desirable goal of hypertension management and that the stratification of hypertensive patients based on arterial stiffness level can improve hypertension treatment. Further research is needed to clarify the biologic basis of these observations.
